glp-1 obesity drug news today september 29 2025 The FDA approved a new pill from Eli Lilly on Wednesday. The drug, called Foundayo, is the second GLP-1 weight-loss pill. CBS News' Dr. LaPook has more on the new medication Approved 20 years ago as

It's been studied since the 1960s, originally found in the thymus gland (hence thymosin)

Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ The GH/IGF-1 axis in ageing and longevity

Individual molecular species of CE were analyzed using multiple reaction monitoring transitions and quantified according to the reference standard and reported as mol/g liver tissue

17 If you want the research behind this, it backs it up: a placebo-controlled double-blind RCT by Lenzi et al

From topical research: Most commonly reported observation: mild transient redness at application site (attributed to vascular activity from VEGF stimulation) No systemic adverse events reported in human topical studies at standard concentrations No evidence of carcinogenicity or mutagenicity in available in vitro models From injectable research (preclinical): At supratherapeutic doses in animal models, mild injection site reactions have been noted No organ toxicity observed in standard preclinical safety panels No immunogenicity concerns identified (consistent with its endogenous structure) Copper considerations: GHK-Cu delivers a small amount of bioavailable copper